title: [Mechanism of c-MET in Non-small Cell Lung Cancer and Its Treatment and Testing].
abstract: Hepatocyte growth factor/c-MET (HGF/c-MET) signaling pathway can be abnormal activated by many mechanisms such as c-MET mutation, amplification and the overexpression of HGF, and it plays an important role in the development of non-small cell lung cancer (NSCLC), as well as in the tolerance of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in NSCLC. Therefore, c-MET is a new molecular target for the therapy of NSCLC since EGFR and ALK. At present, although the c-MET inhibitors have shown a potential prospect in some clinical trials, its assessment of safety and effectiveness in clinical applications, and the choice of testing methods and standards still need a further discussion. In this paper, we summarized the mechanism of c-MET in NSCLC, as well as its treatment prospect and selection of testing methods.
authors.affiliation: Chinese Academy of Medical Sciences, Chinese Peking Union Medical College, Peking Union Medical College Hospital,  Beijing 100730, China.
authors.forename: Hongge
authors.initials: H
authors.lastname: Liang
authors.affiliation: Chinese Academy of Medical Sciences, Chinese Peking Union Medical College, Peking Union Medical College Hospital,  Beijing 100730, China.
authors.forename: Mengzhao
authors.initials: M
authors.lastname: Wang
mesh_terms: D000818:Animals; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000201:enzymology* / Q000235:genetics; D004791:Enzyme Inhibitors / Q000008:administration & dosage; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000201:enzymology* / Q000235:genetics; D009154:Mutation; D019859:Proto-Oncogene Proteins c-met / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism*
chemical_list: D004791:Enzyme Inhibitors; D019859:Proto-Oncogene Proteins c-met